A new Hollywood biopic directed by Danny Boyle provides a glossy, fictionalized yet revealing glimpse of the human being behind Apple’s iconic products. A recent documentary has a harder critical edge. Four years after his death, Jobs’ flawed genius defies categorization.
Ambrose Bierce wrote “The Devil’s Dictionary” a century ago, ranging acerbically across government, commerce and life. Breakingviews’ original re-use of the form for finance – in 2007, when the crisis was barely beginning – is no longer adequate. Herewith part one of the sequel.
The Chinese e-commerce group is a minority investor in the business that arranges delivery of billions of its packages. Yet Alibaba has spent over $6.3 bln on logistics-related deals in the past three years. Even if the investments make strategic sense, shareholders are in the dark.
U.S. officials haven’t collected employer training information in two decades. It’s one example of a larger problem. Peter Scher, JPMorgan’s head of corporate responsibility, says more public and private funding of data gathering and analysis would help the U.S. economy grow.
U.N. goals, a U.S.-China pact and papal concern are all fine ways to highlight global development issues. The problem is financing the $4 trln a year needed to solve the issues. The BoE governor’s idea to make companies lay out climate-change risks is one promising approach.
The German carmaker skidded into a legal system that extracts bigger fines and more guilty pleas from overseas companies than American peers. Differences in the cases may explain the discrepancy. But any prosecutor bias may get as much scrutiny as Volkswagen’s emissions tricks.
Seven years on and the financial crisis blame game is still alive and well. In his new film, “99 Homes,” Ramin Bahrani crafts a dramatic narrative that does the best job yet of capturing the complexity of assigning accountability to the collective U.S. housing delusion.
The People’s Republic’s taste for hog DNA was touted as a 45 million pound win for UK trade back in 2013. Two years later, the results have fallen woefully short. Trade and investment are real, but the more important stuff happens when politicians get out of the way.
Shire’s $30 bln offer for Baxalta is the latest in a string of deals for firms targeting uncommon diseases. Therapies costing over $400,000 a patient and regulatory incentives encourage fast growth and acquisitions. Price pushback on parasite and TB drugs showcases one big risk.
The landmark privatisation is Japan’s biggest listing in decades. Floating the postal operator, plus stakes in its banking and insurance arms, could raise $11.5 bln. But growth is low and follow-on share sales loom. Successful delivery requires low valuations and high dividends.